- Home
- IGMS vs PMVP Comparison
IGMS vs PMVP Comparison
Compare IGMS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- PMVP
- Stock Information
- Founded
- IGMS 1993
- PMVP 2013
- Country
- IGMS United States
- PMVP United States
- Employees
- IGMS N/A
- PMVP N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- IGMS Health Care
- PMVP Health Care
- Exchange
- IGMS Nasdaq
- PMVP Nasdaq
- Market Cap
- IGMS 82.1M
- PMVP 71.9M
- IPO Year
- IGMS 2019
- PMVP 2020
- Fundamental
- Price
- IGMS $1.38
- PMVP $1.41
- Analyst Decision
- IGMS Hold
- PMVP Strong Buy
- Analyst Count
- IGMS 8
- PMVP 3
- Target Price
- IGMS $6.14
- PMVP $5.33
- AVG Volume (30 Days)
- IGMS 368.0K
- PMVP 108.7K
- Earning Date
- IGMS 03-06-2025
- PMVP 03-07-2025
- Dividend Yield
- IGMS N/A
- PMVP N/A
- EPS Growth
- IGMS N/A
- PMVP N/A
- EPS
- IGMS N/A
- PMVP N/A
- Revenue
- IGMS $2,918,000.00
- PMVP N/A
- Revenue This Year
- IGMS $26.85
- PMVP N/A
- Revenue Next Year
- IGMS $125.17
- PMVP N/A
- P/E Ratio
- IGMS N/A
- PMVP N/A
- Revenue Growth
- IGMS 57.64
- PMVP N/A
- 52 Week Low
- IGMS $1.26
- PMVP $1.32
- 52 Week High
- IGMS $22.50
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- IGMS 26.21
- PMVP 47.85
- Support Level
- IGMS $1.26
- PMVP $1.36
- Resistance Level
- IGMS $1.54
- PMVP $1.47
- Average True Range (ATR)
- IGMS 0.13
- PMVP 0.05
- MACD
- IGMS 0.22
- PMVP 0.00
- Stochastic Oscillator
- IGMS 29.27
- PMVP 52.17
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.